Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.
about
Azilsartan Improves Salt Sensitivity by Modulating the Proximal Tubular Na+-H+ Exchanger-3 in MiceReassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockersStructure of the Angiotensin receptor revealed by serial femtosecond crystallography.International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin ReceptorBiased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and PathologyAn evaluation of the latest evidence relating to renin-angiotensin system inhibitors.Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?Recent progress in the treatment of cardiovascular disease using olmesartan.Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide.Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms.Preclinical research strategies for newly approved drugs as reflected in early publication patterns.Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.Liquid chromatography/tandem mass spectrometry study of forced degradation of azilsartan medoxomil potassium.Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.Ability of the new AT1 receptor blocker azilsartan to block angiotensin II-induced AT1 receptor activation after wash-out.Effects of azilsartan compared to other angiotensin receptor blockers on left ventricular hypertrophy and the sympathetic nervous system in hemodialysis patients.
P2860
Q28602057-B0F14E15-C015-44AD-816D-764A3C952B39Q35048773-D3579D05-9DA9-4C8A-A378-F71AF86683CBQ35592165-3B9D27E3-BA6B-44B0-B085-78371DE56480Q36241932-1E9AC5D6-8C11-42BA-A68E-96CA6258020CQ36443983-E807B0B6-A5C5-4740-9CAA-F775E17F4D83Q37551908-91DCF825-C278-48C1-A97E-397ADAC2CA5EQ38096442-BD0D5554-D067-48A7-8BF8-BDC1B4108F3EQ38144197-8E234A82-3B8F-41A6-A0FB-038C7E7C72EAQ38155920-371059B5-693A-492F-8745-7B41C1CD52D0Q38286387-BD2E17F7-9874-4294-AC3B-BBE2894A480EQ38336214-337CF616-DB5C-4B32-A7B3-D24EFCDEAF49Q38411081-B910095C-ED89-4669-8E89-35DCA04335C9Q38781028-6F9835C4-0161-49E1-B872-D6CEACFAED3AQ40765639-8B0E66D5-2383-41DA-9126-08BE67D8B822Q41922933-A5948348-27CB-46D6-BD76-276ED716EFC7Q44587419-DDCF8CD2-8A0F-4220-95C9-E343D611FB40Q48123657-C7E8DADA-11A6-4F4B-8A79-99DFB1943C0C
P2860
Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Unique binding behavior of the ...... ared with that of candesartan.
@en
type
label
Unique binding behavior of the ...... ared with that of candesartan.
@en
prefLabel
Unique binding behavior of the ...... ared with that of candesartan.
@en
P2093
P2860
P356
P1476
Unique binding behavior of the ...... ared with that of candesartan.
@en
P2093
Atsutoshi Okabe
Keijiro Saku
Sadashiva S Karnik
Shin-ichiro Miura
Yoshino Matsuo
P2860
P2888
P304
P356
10.1038/HR.2012.147
P577
2012-10-04T00:00:00Z
P5875
P6179
1029943190